Growth-Signalling Comparison Matrix
The growth-signalling catalogue contains different receptor classes and different molecular strategies. CJC-1295 No DAC/Modified-GRF-type material and tesamorelin belong to GHRH-receptor research, while ipamorelin belongs to the growth-hormone-secretagogue/ghrelin-receptor class. A blend that combines two classes is a separate experimental condition, not a new single mechanism.
Growth-signalling research matrix
| Feature | CJC-1295 No DAC | Ipamorelin | Tesamorelin |
|---|---|---|---|
| Broad class | Modified-GRF(1-29)-type GHRH analogue | Growth-hormone secretagogue / ghrelin-receptor agonist context | Modified GHRF(1-44)-type analogue |
| Primary pathway question | Temporally bounded GHRH-receptor perturbation | GHS-receptor secretagogue pharmacology and selectivity | GHRH-receptor biology with an N-terminal stability modification |
| Key structural issue | Exact sequence/substitutions and absence of albumin-binding DAC must be documented | Exact pentapeptide form and product identity must be documented | Exact TH9507/tesamorelin form and N-terminal modification must be documented |
| Evidence caution | Do not import pharmacokinetics from albumin-bound CJC-1295 | Do not generalise selectivity beyond the tested species/assay | Do not equate Core Research RUO material with a regulated medicinal formulation |
| Catalogue | CJC-1295 No DAC 10mg | Ipamorelin 10mg | Tesamorelin 10mg |
GHRH analogues are not one material
Tesamorelin and CJC-1295 No DAC both derive from GHRH biology, but the structural strategies differ. Tesamorelin/TH9507 retains a longer GHRF framework with an N-terminal modification; No-DAC/Modified-GRF-type materials use a shorter sequence with substitutions. The CJC-1295 structural comparison explains why albumin-bound CJC-1295 should also remain separate.
Ipamorelin is a different receptor class
Ipamorelin was developed as a selective growth-hormone secretagogue. In the original pharmacology programme it released GH while producing less ACTH/cortisol response than GHRP-2/GHRP-6 under the tested conditions. PubMed. This makes it useful for a different receptor-signalling question from GHRH analogues.
Compare measurements, not only pathway names. GHRH-receptor activation, GHS-receptor activation, measured growth-hormone release and other endocrine signals are related but distinct endpoints. The original ipamorelin pharmacology study compared selected hormone responses under specified experimental conditions; it does not establish identical receptor selectivity in every species or assay. A research plan should identify its exact molecular material, model, receptor/readout and comparator before treating results for these three catalogue entries as comparable.
The CJC-1295 No DAC + Ipamorelin blend
The CJC-1295 No DAC + Ipamorelin 10mg product contains two named research constituents. Separate receptor-class evidence can explain the rationale for studying them together, but it does not prove synergy, a fixed combined kinetic profile or a specific organism-level outcome.
Choosing the correct material
- Define whether the question concerns GHRH-receptor or GHS-receptor signalling—or both.
- Specify the exact molecular form used in the literature.
- Match the model and endpoint rather than selecting by catalogue category alone.
- For a blend, retain constituent-level controls if attribution matters.
- Use product/lot documentation for commercial material identity.
Research-use boundary
This matrix does not rank materials for muscle growth, fat loss, performance, safety or effectiveness and gives no dosing or administration protocol. Core Research materials are supplied for laboratory research use only.